SEC Form 4 · accession 0001140361-26-036347
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Magrath
Officer — Chief Executive Officer · Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001228627
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 9, 2026 | M | 392,157 | $1.15 | A | 2,124,026 | D | |
| Common Stock | Sep 9, 2026 | F | 75,541 | $5.97 | D | 2,048,485 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy)F2 | $1.15 | Sep 9, 2026 | M | 392,157 | D | — | Mar 25, 2030 | Common Stock | 392,157 | 0 | D |
Explanation of responses
- F1The Reporting Person paid the exercise price of the Warrant on a cashless basis. The Issuer withheld 75,541 shares, calculated in accordance with the terms of the Warrant, to pay the exercise price and issued the remaining 316,616 shares to the Reporting Person.
- F2The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.